Welcome to our dedicated page for Keen Vision Acquisition SEC filings (Ticker: kvacw), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Keen Vision Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Keen Vision Acquisition's regulatory disclosures and financial reporting.
Keen Vision Acquisition Corporation entered into a financing arrangement with its sponsor to extend the time it has to complete a business combination.
On April 21, 2026, the company issued an unsecured promissory note for $120,000 to KVC Sponsor LLC. The sponsor deposited the same amount into the company’s trust account, allowing the business combination deadline to be extended. The note bears no interest and becomes due at the closing of a business combination. The holder may convert the note into units identical to the IPO units at $10.00 per unit. By depositing $120,000 into the trust account on April 27, 2026, the company extended its business combination period to July 27, 2026.
Keen Vision Acquisition Corporation entered into a financing arrangement with its sponsor to extend the time it has to complete a business combination.
On April 21, 2026, the company issued an unsecured promissory note for $120,000 to KVC Sponsor LLC. The sponsor deposited the same amount into the company’s trust account, allowing the business combination deadline to be extended. The note bears no interest and becomes due at the closing of a business combination. The holder may convert the note into units identical to the IPO units at $10.00 per unit. By depositing $120,000 into the trust account on April 27, 2026, the company extended its business combination period to July 27, 2026.
Keen Vision Acquisition Corporation reported that it amended its binding letter of intent with Medera Inc. and its subsidiary Novoheart Group Limited. The amendment moves the target date to sign a new replacement merger agreement from April 10, 2026 to April 30, 2026.
The prior merger agreement dated September 3, 2024 had already been terminated and replaced by this letter of intent. The parties continue to use their best efforts to finalize and execute the replacement merger agreement by the new deadline.
Keen Vision Acquisition Corporation reported that it amended its binding letter of intent with Medera Inc. and its subsidiary Novoheart Group Limited. The amendment moves the target date to sign a new replacement merger agreement from April 10, 2026 to April 30, 2026.
The prior merger agreement dated September 3, 2024 had already been terminated and replaced by this letter of intent. The parties continue to use their best efforts to finalize and execute the replacement merger agreement by the new deadline.
Keen Vision Acquisition Corporation entered into a binding letter of intent with Medera Inc. and its subsidiary Novoheart Group Limited (NVH) to negotiate a replacement merger agreement. The new deal would combine NVH, a pre-clinical human disease modeling and drug discovery business, with Keen Vision, which would remain Nasdaq-listed.
The LOI sets NVH’s enterprise valuation at US$100,000,000 and requires the surviving company to have at least US$10,000,000 of available cash at closing after expenses and NVH-related debt. Cash expenses paid at closing are capped at US$700,000 for Keen Vision and US$1,300,000 for NVH, with liquidity coming from the trust account after redemptions, any PIPE financing, and NVH’s cash.
The parties aim to sign the replacement merger agreement by April 10, 2026, with closing conditions largely mirroring a prior merger agreement that has now been terminated under a mutual release. The deal must close within nine months of the LOI, and any PIPE fundraising must also be completed within nine months of signing.
Keen Vision Acquisition Corporation entered into a binding letter of intent with Medera Inc. and its subsidiary Novoheart Group Limited (NVH) to negotiate a replacement merger agreement. The new deal would combine NVH, a pre-clinical human disease modeling and drug discovery business, with Keen Vision, which would remain Nasdaq-listed.
The LOI sets NVH’s enterprise valuation at US$100,000,000 and requires the surviving company to have at least US$10,000,000 of available cash at closing after expenses and NVH-related debt. Cash expenses paid at closing are capped at US$700,000 for Keen Vision and US$1,300,000 for NVH, with liquidity coming from the trust account after redemptions, any PIPE financing, and NVH’s cash.
The parties aim to sign the replacement merger agreement by April 10, 2026, with closing conditions largely mirroring a prior merger agreement that has now been terminated under a mutual release. The deal must close within nine months of the LOI, and any PIPE fundraising must also be completed within nine months of signing.
Keen Vision Acquisition Corporation reported that the sponsor of its initial public offering, or its designee, wired $144,670.38 on August 27, 2025 into the company’s trust account for public shareholders. This trust account holds funds for the benefit of public investors in the company’s units, ordinary shares, and warrants listed on Nasdaq.
This cash contribution increases the amount held in trust for public shareholders and reflects ongoing sponsor support of the structure established at the IPO.
Keen Vision Acquisition Corporation filed a Form 8-K reporting a material event related to its warrants. The filing identifies trading symbols for its units, ordinary shares and warrants as KVACU, KVAC and KVACW and lists an exhibit: a Promissory Note dated August 18, 2025 included as Exhibit 10.1. The document bears a signature from Chief Executive Officer Kenneth Ka Chun Wong dated August 22, 2025. The text provided does not include the promissory note's financial terms, amounts, counterparties, or any discussion of material financial impact, so the filing's substantive details and investor implications cannot be determined from the content provided.
Mizuho Financial Group reported beneficial ownership of 973,800 common shares of Keen Vision Acquisition Corporation, representing 9.0% of the class. The filing shows sole voting and sole dispositive power over all 973,800 shares, and identifies the reporting person as a parent holding company organized in Japan.
The filing is a Schedule 13G/A disclosure and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control. The schedule also notes that Mizuho Securities USA LLC directly holds the securities and related Mizuho entities may be deemed indirect beneficial owners.
Keen Vision Acquisition Corporation (KVAC) held $73,062,664 in its Trust Account as of June 30, 2025, up from $70,373,065 at year-end, producing dividend income that contributed to net income of $1,126,226 for the six months ended June 30, 2025 versus $5,040,728 in the prior year period. The company entered into a Merger Agreement to combine with Medera Inc., valuing 100% of Medera at $622,560,000 with an implied Acquirer share value of $10.00. Management has repeatedly deposited extension payments into the Trust Account (multiple $200,000 deposits and a $144,670 deposit on July 23, 2025) to extend the business combination deadline to August 27, 2025. The company reported a working capital deficit of $2,772,485 and minimal cash at bank ($1,317), and discloses substantial doubt about its ability to continue as a going concern if a business combination is not completed by the deadline.
Keen Vision Acquisition Corporation: W. R. Berkley Corporation and its subsidiary Berkley Insurance Company each report beneficial ownership of 1,046,168 ordinary shares, representing 9.7% of the outstanding class based on the issuer's reported 10,820,727 ordinary shares outstanding. The holders disclose shared voting power and shared dispositive power over 1,046,168 shares and report zero sole voting and zero sole dispositive power.
The filers certify the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The disclosure is made on Schedule 13G/A by W. R. Berkley Corporation and Berkley Insurance Company.